Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy

Intralesional chemotherapy for nonmelanoma skin cancer: A practical review

“…In general, injections are placed strategically to infiltrate the periphery and base of the tumor. 21,37,53 Blanching of the tumor and a peau d'orange change serve as clinical markers for effective infiltration. Large or multiple tumors may require a volume of medication that approaches the maximum recommended dose.…”

“…Seven had elevated liver function test results and 3 had changes in their complete blood cell count; none discontinued therapy and all changes normalized 5 weeks after treatment. 53 Side effects were not noted in those receiving the lowest treatment dose of 0.9 mU 51 but occurred in 65% of those receiving 1.5 mU per treatment. 53 KA and interferon alfa.…”

“…53 Side effects were not noted in those receiving the lowest treatment dose of 0.9 mU 51 but occurred in 65% of those receiving 1.5 mU per treatment. 53 KA and interferon alfa. Three articles reported the use of interferon alfa-2, -2a, or -2b for treatment of KA.…”

“…In all, 31 invasive SCCs and 9 SCCis treated with interferon alfa-2 or -2b were reported in 3 articles. 47,51,53 The location of the tumors, when specified, was on the legs, hand/digit, ear, or other site with surrounding sun damage. All cases had a pretreatment biopsy.…”

Off-label uses of biologics in dermatology: Interferon and intravenous immunoglobulin (Part 1 of 2)

“…3,[7][8][9][10][11][12][13] A summary of these studies can be found in Table III. Interferon therapy, which produces excellent cosmetic results through minimal invasiveness and scarring, should be considered an effective alternative therapy for SCCs. The cure rate for early stage SCC with intralesional interferon alfa in one openlabel study involving 36 SCCs was 88%.…”